SCHEMBL2873329

SCHEMBL2873329

Cc1ccc(Nc2c(-c3cccnc3)nc3c(C#N)c[nH]n23)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 9/20 0.56
▸ GAA P10253 6/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ TP53 P04637 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MAPT P10636 3/20 0.46
▸ MAPK1 P28482 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ KDM6B O15054 1/20 0.40
▸ KDM5C P41229 1/20 0.40
▸ KDM5D Q9BY66 1/20 0.40
▸ KDM4C Q9H3R0 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.40
▸ PHF8 Q9UPP1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124746 0.89 KDM5A (0.52) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2124502 0.88 KDM5A (0.53) KDM5AGAAKDM4ETP53SMN1; SMN2
SCHEMBL2124903 0.83 KDM5A (0.57) KDM5AGAATP53MAPTKDM6B
SCHEMBL2124897 0.83 KDM5A (0.56) KDM5AGAATP53MEN1KMT2A
SCHEMBL2122447 0.83 KDM5A (0.53) KDM5AGAATP53MAPTPOLB
SCHEMBL2123179 0.82 KDM5A (0.58) KDM5ATP53MAPTPOLBKDM6B
SCHEMBL2127506 0.82 MAPT (0.54) KDM5AKDM4ETP53MEN1KMT2A
SCHEMBL2124763 0.82 KDM5A (0.47) KDM5AGAATP53SMN1; SMN2MAPT
SCHEMBL2124375 0.82 MAPT (0.45) KDM5AGAATP53MAPTPOLB
SCHEMBL2122557 0.82 MAPT (0.45) KDM5AGAATP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885GAA 502/4885KDM4E 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback